255 results
424B5
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Prospectus supplement for primary offering
4:32pm
in the prospectus supplement, naming the underwriter, the nature of any such relationship.
We may sell securities directly or through agents we designate from time
8-K
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
risks: the nature and scope of additional feedback or information requests from the FDA; that the time and resources required to respond
8-K
EX-1.1
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
of the nature contemplated by Section 10(a)(ii) effected without its written consent if (1) such settlement is entered into more than 45 days after receipt
424B5
gz84ck
6 Feb 24
Prospectus supplement for primary offering
9:25am
8-K
EX-99.1
d20t5jlgta pvui
11 May 23
LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:10pm
8-K
EX-10.1
imamm059497ek
17 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
EX-10.2
lxcqgfcx
17 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm